Last reviewed · How we verify
Rosuvastatin and Furosemide- Part C
Rosuvastatin and Furosemide- Part C is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.
At a glance
| Generic name | Rosuvastatin and Furosemide- Part C |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rosuvastatin and Furosemide- Part C CI brief — competitive landscape report
- Rosuvastatin and Furosemide- Part C updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Rosuvastatin and Furosemide- Part C
What is Rosuvastatin and Furosemide- Part C?
Rosuvastatin and Furosemide- Part C is a Small molecule drug developed by AstraZeneca.
Who makes Rosuvastatin and Furosemide- Part C?
Rosuvastatin and Furosemide- Part C is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
What development phase is Rosuvastatin and Furosemide- Part C in?
Rosuvastatin and Furosemide- Part C is in Phase 1.